Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.20 USD

28.20
32,890,660

-0.51 (-1.78%)

Updated Aug 16, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exelixis's Cabometyx Positive for First-Line Kidney Cancer

by Zacks Equity Research

Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

    J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

    by Zacks Equity Research

    Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

      The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

        Arpita Dutt headshot

        3 Biotech Stocks That More than Doubled Year to Date

        by Arpita Dutt

        Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.

          Arpita Dutt headshot

          Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

          by Arpita Dutt

          Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

            Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

            by Zacks Equity Research

            Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

              Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II

              by Zacks Equity Research

              Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).

                Pfizer & Lilly Get Fast Track Designation for Pain Candidate

                by Zacks Equity Research

                Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

                  Company News for June 14, 2017

                  by Zacks Equity Research

                  Companies in the News are: LLY,PFE,CAKE,JW.A,CVCO

                    Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

                    by Zacks Equity Research

                    Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.

                      AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

                      by Zacks Equity Research

                      AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

                        Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.

                        by Zacks Equity Research

                        Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).

                          Roche Announces Data on Perjeta, Alecensa and Tecentriq

                          by Zacks Equity Research

                          Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.

                            Merck's Cancer Drug Keytruda Positive in Clinical Studies

                            by Zacks Equity Research

                            Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

                              Pfizer Provides Final Update on Phase II Talazoparib Study

                              by Zacks Equity Research

                              Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity

                                Pfizer (PFE) Down 2.5% Since Earnings Report: Can It Rebound?

                                by Zacks Equity Research

                                Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

                                  by Zacks Equity Research

                                  Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More

                                    by Arpita Dutt

                                    Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.

                                      Pfizer's Trumenba Vaccine Approved by European Commission

                                      by Zacks Equity Research

                                      Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).

                                        Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

                                        by Zacks Equity Research

                                        Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

                                          Celldex's Immuno-Oncology Pipeline Continues to Impress

                                          by Zacks Equity Research

                                          On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

                                            by Arpita Dutt

                                            Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

                                              Aerie's Ophthalmic Candidate Positive in Registration Trial

                                              by Zacks Equity Research

                                              Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.

                                                Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                                                by Zacks Equity Research

                                                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                                                  Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

                                                  by Zacks Equity Research

                                                  Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.